What it is:COVID-19 is the illness caused by SARS-CoV-2, a respiratory virus that spreads mainly through droplets and aerosols at close range. Presentation ranges from asymptomatic to fatal, and the drug you reach for depends entirely on where the patient sits on that spectrum, not on a single "COVID protocol."
The core problem:Early disease is a viral replication problem. Late, severe disease is an immune overreaction problem. Those are opposite problems needing opposite tools, an antiviral early, an anti-inflammatory late, and giving the wrong one at the wrong phase doesn't just fail to help, it can actively hurt.
What you do about it:Outpatient and mild-moderate disease: shut down viral replication fast (antiviral or monoclonal antibody, started within days of symptom onset). Hospitalized and hypoxic: add anti-inflammatory therapy on top of supportive care, and stop giving antivirals once the patient is critically ill, because by then the virus isn't the problem anymore.
Think of COVID-19 treatment as a timing problem, not a drug-selection problem. Every major treatment mistake in this chapter is a timing mistake: giving remdesivir to a mechanically ventilated patient (too late, virus already cleared, now it's all inflammation), giving corticosteroids to a patient breathing room air (too early, you suppress a response that isn't hurting anyone yet), or reaching for an oral antiviral on day 7 of symptoms (window closed, no more efficacy data to support it).
COVID-19 progresses through three phases of escalating severity, and each phase has a different dominant driver. That's the whole reason the treatment algorithm looks the way it does.
| Phase | Driver | What's happening |
|---|---|---|
| 1. Early infection | Viral replication | Inoculation, incubation, mild symptoms (fever, cough, dyspnea) |
| 2a. Pulmonary, no hypoxia | Localized lung inflammation, continued viral replication | Moderate symptoms, bilateral ground-glass opacities on imaging |
| 2b. Pulmonary, with hypoxia | Same, plus SpO₂ ≤94% | Poorer prognosis marker, this is the line that changes management |
| 3. Hyperinflammation | Cytokine storm | Severe symptoms, systemic inflammation, organ damage |
In phase 1 and early phase 2, monocytes and neutrophils are recruited to the lung and macrophages start pumping out IL-6 and other cytokines, but the virus itself is still the main problem. That's why direct antivirals(nirmatrelvir/ritonavir, remdesivir, molnupiravir) and monoclonal antibodiesthat supplement the immune response work here. By phase 3, IL-1, IL-2, IL-6, G-CSF, and TNF-α are circulating at high levels (the "cytokine storm"), driving pulmonary vascular leakage, alveolar wall fibrosis, edema, and thrombus formation. The virus is no longer the main event, the immune system's own overreaction is. That's why phase 3 calls for corticosteroids, IL-6 inhibitors, and JAK inhibitorsinstead.
Most COVID deaths trace back to this cascade ending in ARDS with hypoxic respiratory failure. Critically ill patients frequently pick up injury to other organs too, heart, brain, liver, kidneys, GI tract, plus a coagulopathy that can look like DIC (dysrhythmias, MI, heart failure, cardiogenic shock, PE, DVT, encephalopathy are all on the differential once a patient is this sick).
Some patients have symptoms that persist for months after the acute illness resolves. Three theorized mechanisms drive it: (1) persistence of SARS-CoV-2 in tissuedue to immune evasion, (2) ongoing inflammation, and (3) ongoing microvascular clotting. None of these are fully proven, but all three point toward long COVID being a biological aftermath, not a psychosomatic one, which matters for how you counsel patients who feel dismissed.
Incubation runs 2 to 14 days, median 4-5 days. From there, presentation spans the entire spectrum: asymptomatic, presymptomatic, mild, moderate, severe, critical, death. Severity can take days to weeks to fully declare itself, which is exactly why early risk stratification and early treatment matter so much.
| Timepoint | What happens |
|---|---|
| Median 7 days after onset | 40%of patients progress to feeling short of breath |
| Median 10 days after onset | 14%progress to severe disease, 5%progress to critical illness |
| Common (often together) | Less common |
|---|---|
| Runny nose, headache, sore throat, sneezing, cough | Fever/chills, fatigue, sputum production, myalgia, dyspnea, diarrhea, nausea/vomiting, abdominal pain, new loss of taste or smell |
Notice that the most commonsymptoms (runny nose, sore throat, sneezing) look like a garden-variety upper respiratory infection, while the "classic" symptoms people associate with COVID, fever, anosmia, dyspnea, are actually less common. Don't anchor on anosmia as a rule-in or rule-out finding.
NAAT (RT-PCR)is the gold standard, detecting viral genetic material from a nasopharyngeal, oropharyngeal, sputum, bronchoalveolar, or saliva sample. Antigen immunoassaysare the alternative, faster but less sensitive, and indicate active or recent infection. Serologic (antibody) testingis complementary, it shows past infection and/or vaccination, not active disease, and is collected by fingerstick or venipuncture.
A patient can be diagnosed with probable COVID-19based on a compatible clinical syndrome even with a negative or absent test. False negatives are most common earlyin infection, before viral load has built up, so a single negative test on day 1-2 of symptoms doesn't rule anything out.
Abnormalities on all of the above become more numerous and more pronounced as disease severity increases, so trending labs is as useful as any single value.
There's no formal staging system here the way there is for CKD or heart failure. Instead, treatment eligibility is organized around where the patient is and how much oxygen they need. Get this classification right and the rest of the chapter falls into place.
| Severity | Definition | Antivirals / mAb | Immunomodulators | Anticoagulation |
|---|---|---|---|---|
| Mild-moderate, not hospitalized | Outpatient or ED, no supplemental O₂ above baseline | Pick one: nirmatrelvir/ritonavir, bebtelovimab, or remdesivir, if high-risk for hospitalization | No | No |
| Moderate, hospitalized | No supplemental O₂ above baseline, radiographic pneumonia | Remdesivir not routine; consider in high-risk patients (3-5 day course) | No | Avoid unless otherwise indicated |
| Severe, hospitalized | Requires supplemental O₂ or non-invasive ventilation | Remdesivir yes on low-flow O₂ (5 days); no on HFNC/NIV | Corticosteroid yes; add tocilizumab or baricitinib if rapidly rising O₂ needs or CRP ≥75 mg/L | Low-flow O₂: yes. HFNC/NIV: avoid unless otherwise indicated |
| Severe-critical, hospitalized | Mechanically ventilated, ECMO, septic shock, and/or multi-organ dysfunction | No, to all three, large trials showed no benefit and possible harm | Corticosteroid yes; tocilizumab or baricitinib if recently intubated and hasn't received either yet | Avoid unless otherwise indicated |
Patients breathing ambient air should not receive corticosteroids.There's no inflammation to blunt yet and steroids only add risk. And never give both tocilizumab and baricitinib together, pick one, and only ever layer it on top of a corticosteroid, since benefit hasn't been shown for either agent without steroid backbone.
Goals:prevent progression to severe disease requiring hospitalization or death, and speed symptom resolution.
Three anti-SARS-CoV-2 therapies are available outpatient, and the whole point is starting them fast. Two are 5-day oral courses, one is a 3-day IV infusion.
Oral. Strong CYP3A4/P-gp inhibitor, check every interaction.
Monoclonal antibody, no drug interactions.
IV antiviral, the only 3-day outpatient option.
Only if the three preferred options are all unavailable.
Only give oneEUA therapy per patient. Choice between the preferred three comes down to patient characteristics and preferences, drug interactions, and what's actually in stock. Molnupiravir drops to the bottom of the list because its efficacy data is weaker.
The FDA authorized pharmacists to prescribe nirmatrelvir/ritonavir directly under the EUA, as long as there's no drug interaction requiring modification and renal/hepatic function can be assessed. Several states built formal infrastructure around this: Oregon's Public Health and Pharmacy Formulary Advisory Committee (PHPFAC), for example, maintains a standalone "SARS-CoV-2 Antiviral" statewide protocol so a community pharmacist can independently assess, treat, and document without waiting on a prescriber. That's the kind of access point that actually gets a patient dosed inside the 5-day window instead of missing it.
Ivermectin, hydroxychloroquine or chloroquine, azithromycin, inhaled corticosteroids, and supplements (vitamin D, vitamin C, vitamin K, zinc, melatonin) should not be used for outpatient COVID-19. Fluvoxamine has unclear benefit and isn't routinely recommended either. This is a favorite distractor list on exams because several of these sound plausible.
Goals:survival, avoiding mechanical ventilation or ICU admission, and shortening length of stay.
Remdesiviris recommended for hospitalized patients requiring supplemental oxygen or non-invasive ventilation only, it is notrecommended for mechanically ventilated patients. Standard course is 5 days or until discharge; guidelines allow extending to 10 days if there's no substantial improvement by day 5, though that's rarely done in practice since the supporting data is thin.
Patients should notbe kept in the hospital just to finish a remdesivir course. Discharge them when they're medically ready and let outpatient logistics catch up, not the other way around.
Dexamethasoneis added once a patient needs supplemental oxygen, 10 days or until discharge or until oxygen support is no longer required, whichever comes first. Discontinue it as soon as the oxygen requirement resolves. Corticosteroids are withheld in patients breathing ambient air because of potential harm without any offsetting benefit.
Tocilizumab(an IL-6 receptor blocker) or baricitinib(a JAK inhibitor) get added on top of dexamethasone, never instead of it, for patients with rapidly rising oxygen needs (heading toward HFNC or NIV) and/or markedly elevated inflammatory markers (CRP ≥75 mg/L). Pick one, not both, and reserve them for patients who haven't already received one during the admission.
Therapeutic-dose heparin or LMWH is recommended for nonpregnant, hospitalized patients requiring supplemental oxygen who have an elevated D-dimer and aren't at increased bleeding risk. Everyone else on supplemental oxygen or higher-level respiratory support (HFNC, NIV, or mechanical ventilation) who doesn't meet that profile gets prophylactic-dose heparin instead.
Large randomized trials found no benefit and possible harmfrom therapeutic-dose anticoagulation in mechanically ventilated patients. Same logic as the antiviral cutoff: once a patient is this sick, the virus and the clot risk calculus have both changed, and more aggressive therapy stops helping.
| Monoclonal antibody (outpatient) | ||
| Bebtelovimab | 175 mg IV, once | Can infuse as fast as 30 seconds; within 7 days of onset |
| Oral antivirals (outpatient) | ||
| Nirmatrelvir/ritonavir | 300 mg/100 mg PO BID × 5 days | eGFR <30: not authorized; within 5 days of onset |
| Molnupiravir | 800 mg PO BID × 5 days | Alternative only; avoid in pregnancy; within 7 days of onset |
| Remdesivir (IV, outpatient or inpatient) | ||
| Adults, outpatient | 200 mg IV day 1, then 100 mg IV daily × 2 days (3 total) | Within 7 days of onset |
| Adults, inpatient | 200 mg IV day 1, then 100 mg IV daily | 5 days or until discharge; may extend to 10 days if no improvement by day 5 |
| Pediatrics 3-40 kg | 5 mg/kg IV day 1 (max 200 mg), then 2.5 mg/kg IV daily (max 100 mg) | Use lyophilized powder product (less SBECD excipient) for pediatrics |
| Immunomodulators (inpatient, severe-critical disease only) | ||
| Dexamethasone, adults | 6 mg IV or PO once daily | 10 days or until discharge or no longer needs O₂; discontinue once O₂ no longer required |
| Dexamethasone, pediatrics | 0.15 mg/kg PO or IV daily (max 6 mg) | Same duration logic as adults |
| Tocilizumab | 8 mg/kg IV once, actual body weight (max 800 mg) | Only with dexamethasone; never with baricitinib |
| Baricitinib | 4 mg PO once daily × 14 days or until discharge | Renal dose adjustment needed; only with dexamethasone; never with tocilizumab |
Ritonavir is bundled in purely to boost nirmatrelvir levels by inhibiting CYP3A4, but that same inhibition (plus P-gp inhibition) makes this combination one of the most interaction-heavy drugs a pharmacist will encounter. Run every patient through an interaction checker and coordinate with the prescriber on which home meds need to be held or dose-adjusted for the 5-day course.
Adverse effects:dysgeusia (a metallic or bitter aftertaste patients notice almost immediately) and diarrhea. Neither is dangerous, but dysgeusia is common enough that patients should be warned about it upfront or they'll assume something is wrong.
Renal cutoff:requires dose adjustment for reduced renal function and is not authorized if eGFR <30 mL/min. Confirm renal function before dispensing, this is exactly the kind of check a pharmacist prescribing under the EUA is required to perform.
Remdesivir is the one antiviral that spans the entire severity spectrum, from a 3-day outpatient infusion in high-risk mild-moderate disease to a 5-day (or longer) inpatient course in patients needing low-flow supplemental oxygen. The dividing line inpatient is respiratory support level: it's given to patients on low-flow oxygen but withheld once someone escalates to HFNC, NIV, or mechanical ventilation, since trial data showed no benefit (and possible harm from concurrent anticoagulation) at that severity.
Adverse effects:elevated LFTs (transaminitis is the one to monitor for), infusion reactions, bradycardia, hypotension.
Interaction:chloroquine and hydroxychloroquine may theoretically blunt remdesivir's effect, one more reason those two agents don't belong anywhere in the current COVID-19 regimen.
Bebtelovimab supplements the immune response directly with a preformed antibody rather than blocking viral replication the way the oral/IV antivirals do. It's notable for having essentially no drug interactions, which makes it a clean option in patients on complex regimens where nirmatrelvir/ritonavir's CYP3A4 interactions would be a problem. It can be infused as fast as 30 seconds, and the main risk is an infusion-related reaction.
Its authorized window is 7 days from symptom onset, two days longer than nirmatrelvir/ritonavir's 5-day window, which matters when a patient presents a bit later than ideal.
Dexamethasoneis a moderate CYP3A4 inducer with the predictable steroid adverse effect list: hyperglycemia, fluid retention, leukocytosis, dermatologic effects, adrenal suppression, GI hemorrhage or perforation, and amyotrophy/myopathy with prolonged courses. Higher doses (10-20 mg/day) were studied in small trials of severe ARDS but are not currently recommended, stick to 6 mg.
Tocilizumabblocks the IL-6 receptor directly, cutting off the cytokine that's driving the hyperinflammatory phase. It may increase CYP3A4 metabolism of other drugs, and carries bacterial infection and hypersensitivity risk, use caution stacking it with other immunosuppressive therapy the patient may already be on.
Baricitinibis a JAK inhibitor with a broader immunosuppressive footprint. Watch for increased aminotransferases and venous thromboembolism, and adjust the dose for renal impairment. The rule that ties both agents together: only in combination with dexamethasone, never both together, and only in patients who haven't already received one during the admission.
Vaccination is the single best way to cut COVID-19 morbidity and mortality. Masks, social distancing, ventilation, hand washing, and disinfectants are the supporting cast, not substitutes.
| Vaccine | Platform | Primary series |
|---|---|---|
| Pfizer (BNT162b2) | mRNA | Two doses |
| Moderna (mRNA-1273) | mRNA | Two doses |
| Johnson & Johnson (Ad26.CoV2S) | Adenovirus vector | One dose |
| Novavax (NVX-CoV2373) | Adjuvanted recombinant spike protein | Two doses |
Anaphylaxis:4.7 cases per million doses with Pfizer, 2.5 per million with Moderna, rare but why post-vaccination observation exists. Delayed injection-site rash(median onset 8 days, can be large) has been reported with Moderna. Myocarditisis associated with both mRNA vaccines, more frequent after dose 2 and in younger males, tell this population what chest pain or palpitations after vaccination should prompt them to do. J&J: most common effects are injection-site pain, headache, fatigue, myalgia, but watch for thrombosis with thrombocytopenia syndrome (TTS)in women 18-49, roughly 7 cases per million vaccinations, a rare but potentially life-threatening clotting disorder distinct from ordinary VTE.
Guidance in this space moves fast and this chapter's specifics (dose numbers, booster intervals, which vaccines are authorized for which ages) reflect an August 2022 snapshot. The logicholds: mRNA preferred, extra dose for immunocompromise, boosters spaced by months not weeks, but always check current CDC/ACIP recommendations before counseling a real patient on today's schedule.
A serious pediatric complication that shows up afteracute SARS-CoV-2 infection, and looks a lot like Kawasaki disease. Diagnostic picture: fever, elevated inflammatory markers (IL-6, TNF-α), involvement of two or more organ systems, current or recent COVID-19 infection or exposure within the prior four weeks, and no better alternative explanation.
Abdominal pain, vomiting, diarrhea, skin rash, and mucocutaneous lesions are the presenting picture, but in severe cases it progresses to hypotension and shock. Organ involvement can include cardiac dysfunction (myocarditis, cardiogenic shock) and renal dysfunction (AKI). A child with a fever and rash weeks after a mild or even unnoticed COVID infection is the scenario to keep on your radar.
Symptoms persisting more than 4 weeks after acute illness, sometimes for months or years. Also called post-COVID conditions, long-haul COVID, PASC, or chronic COVID. Most common symptoms: fatigue, "brain fog" (self-reported sluggish or fuzzy cognition), dyspnea, headache, chest tightness, numbness/tingling, dysgeusia, myalgia, anosmia, depression/anxiety, chest pain, and variation in heart rate and blood pressure.
Remdesivir use in pregnant patients appears safe based on available data and should be based on clinical judgment weighing benefit against risk. Molnupiravir, by contrast, should notbe used in pregnancy or breastfeeding, patients with reproductive potential need counseling on effective contraception while taking it. Therapeutic anticoagulation recommendations for hospitalized patients specifically exclude pregnant patients, use clinical judgment there instead.
| Parameter | When | Watching for |
|---|---|---|
| SpO₂ (home pulse ox) | Daily during outpatient isolation | Value ≤94% means seek care, this is the single most important home monitoring number |
| LFTs | While on remdesivir | Transaminitis |
| Blood glucose, mental status, signs of infection | While on corticosteroids | Hyperglycemia, neurologic effects, secondary infection |
| Respiratory status / O₂ requirement | Daily inpatient | Whether corticosteroid, tocilizumab, or baricitinib can be de-escalated or stopped |
| Symptom resolution | Ongoing | Hypoxia, fever, cough, and dyspnea trending down |
| Renal function | Before dispensing nirmatrelvir/ritonavir or baricitinib | eGFR <30 blocks nirmatrelvir/ritonavir; baricitinib needs renal dose adjustment |
Report drug adverse events to FDA MedWatch. Report vaccine adverse events to VAERS, especially anything serious or previously unreported. Both are part of standard practice, not optional extra steps.